Who Generates Higher Gross Profit? Pharming Group N.V. or Alkermes plc

A Tale of Two Biopharma Giants: Pharming Group N.V. vs. Alkermes plc

In the competitive world of biopharmaceuticals, gross profit is a key indicator of a company's financial health and market position. Over the past decade, Alkermes plc has consistently outperformed Pharming Group N.V. in generating gross profit. From 2014 to 2023, Alkermes plc's gross profit surged by over 700%, peaking in 2023 with a remarkable $1.41 billion. In contrast, Pharming Group N.V. experienced a more modest growth, with its gross profit increasing by approximately 900% over the same period, reaching $220 million in 2023.

This stark difference highlights Alkermes plc's robust market strategies and operational efficiencies. While both companies have shown growth, Alkermes plc's ability to scale its operations and capitalize on market opportunities has set it apart as a leader in the industry. As the biopharma landscape continues to evolve, these financial metrics offer valuable insights into the strategic directions of these two companies.